Access Reports Data For MuGard Study In Head, Neck Cancer

Speharm, Access’ European partner, is collecting data from a post approval study of MuGard in head and neck cancer patients, undergoing radiation treatment in the UK showing prevention of oral mucositis.

Reportedly, the multi-center seven weeks study of MuGard therapy is expected to enroll 280 patients, where the patients are using MuGard one week prior to their radiation treatment.

Meanwhile, out of the first 140 patients being treated in the study, none of them experienced any oral mucositis.

Jeffrey Davis, president and CEO of Access, said: The initial feedback from SpePharm on their experience in the UK, with the first 140 patients in the assessment study, exceeds our most positive expectations.

Normally, roughly 100% of patients undergoing radiation treatment for head and neck cancer experience some level of oral mucositis. This condition varies from a low level of discomfort and pain, up to Grades 3 and 4 which are debilitating to the point of patients discontinuing therapy. To see a result where all or substantially all of the patients using MuGard, and using it prophylactically, are not getting oral mucositis is extremely important with respect to treatment regimens. We believe the final data set will show that MuGard should be used prophylactically with all radiation or chemotherapy regimens that have the potential to lead to oral mucositis, greatly expanding the target market, he added.